Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Get Free Report) released its quarterly earnings data on Tuesday. The company reported $6.55 earnings per share for the quarter, topping the consensus estimate of ($0.47) by $7.02, Zacks reports. The business had revenue of $15.00 million during the quarter.
Neuphoria Therapeutics Inc. – Common Stock Price Performance
NASDAQ NEUP opened at $5.40 on Wednesday. Neuphoria Therapeutics Inc. – Common Stock has a fifty-two week low of $2.12 and a fifty-two week high of $15.24. The stock has a 50 day simple moving average of $5.13.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright increased their price objective on Neuphoria Therapeutics Inc. – Common Stock from $8.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, February 4th.
About Neuphoria Therapeutics Inc. – Common Stock
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.
Featured Stories
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- 5 discounted opportunities for dividend growth investors
- Rivian Stock Below $20: Charging Up or in the Breakdown Lane?
- Should You Invest in Penny Stocks?
- Best Utilities Stocks for Stability and Growth in 2025
- What does consumer price index measure?
- Qualcomm’s Re-Entry Into the CPU Market May Not Be Enough
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
